Skip to main content

DaVita guidance

  • DVA · NYSE
  • Healthcare
  • Health Care Services
  • S&P 500
$174.22−0.19%Close 16 Nov 2026 · Market value $11.06B

In its results release of 29 Oct 2026 (Q3 FY2026), DaVita gave 2 forecasts in figures, among them operating income (adjusted) of $2.17B to $2.25B for FY2026.

Read from the company's earnings releases and outlook updates of the last two years. Each forecast is shown with the sentence or table row it was read from; what a release does not state in figures is not shown.

Latest guidance given with Q3 FY2026 results, 29 Oct 2026

MeasurePeriodGuidanceAs stated
Operating income · AdjustedFY2026$2.17B to $2.25BAdjusted operating income $2,175 - $2,250
Free cash flowFY2026$1.00B to $1.25BFree cash flow $1,000 - $1,250

Source: the company's earnings release.

Guidance against results above 0 · within 2 · below 0

The last range given before each period closed, how it moved between releases, and the figure then filed. A measure the company defines itself, or one not comparable with the filed figure, has no verdict.

MeasurePeriodLast guidanceRevisionsDeliveredResult
Operating income · AdjustedFY2026$2.17B to $2.25BRaised twice—To come
Free cash flowFY2026$1.00B to $1.25BUnchanged—To come
Operating income · AdjustedFY2025$2.04B to $2.13BNarrowed$2.09BWithin the range
Free cash flowFY2025$1.00B to $1.25BUnchanged$1.02BWithin the range

DVA in the terminal

Guidance said on earnings calls, every revision charted, and guidance set against the analysts' consensus.